Today, DNMT inhibitors such as decitabine and azacytidine, are approved for myelodysplastic syndrome (MDS) and acute myeloid leukaemia and currently under investigation for solid tumours with considerably high toxicity [41]. The gene discussed is DNMT1; the disease is myelodysplastic syndrome.